ACIVIDA -M

Product Description

 ACIVIDA-M is an advanced anti-diabetic medicine formulated with Vildagliptin 50 mg and Metformin 500 mg Sustained Release (SR) for the effective management of Type 2 Diabetes Mellitus. This combination therapy helps regulate blood glucose levels by improving insulin secretion, reducing glucose production in the liver, and enhancing insulin sensitivity. The sustained-release formulation of Metformin ensures gradual release of the medicine, providing prolonged blood sugar control throughout the day. ACIVIDA-M is commonly prescribed along with a healthy diet, regular exercise, and lifestyle modifications to achieve better glycemic control and support long-term diabetes management. Manufactured under stringent quality standards, it offers reliable efficacy and consistent performance, making it a preferred choice among healthcare professionals. Owing to the increasing demand for diabetes care products, ACIVIDA-M is also an ideal product for PCD pharma franchise businesses and pharmaceutical distributors looking to expand their diabetic range with a trusted and high-quality formulation.

Key Composition

The ACIVIDA-M tablets are formulated from the following high-quality ingredients: 

• Vildagliptin 50 mg
• Metformin Hydrochloride 500 mg SR (Sustained Release)

How Vildagliptin and Metformin Tablets  Works

The Vildagliptin and Metformin Sustained Release tablets working mechanism is based on the following process: 

Vildagliptin

Vildagliptin is a DPP-4 inhibitor that increases incretin hormone levels, stimulating insulin release when blood sugar levels rise after meals while reducing glucagon secretion.

Metformin SR

Metformin SR decreases glucose production in the liver, improves insulin sensitivity, and supports better glucose utilization by body tissues. Its sustained-release technology provides gradual drug release for prolonged therapeutic action.

Benefits of ACIVIDA-M

Here are some of the top benefits of Vildagliptin and Metformin  tablets: 

• Helps maintain healthy blood glucose levels.
• Supports improved insulin sensitivity.
• Reduces excess glucose production by the liver.
• Provides prolonged glucose control with sustained-release technology.
• Helps achieve better HbA1c management.
• Suitable for long-term diabetes management under medical supervision.
• Promotes better treatment adherence with controlled drug release.

Therapeutic Uses

Here are Some of the therapeutic uses of the Vildagliptin and Metformin Sustained Release tablet 

• Management of Type 2 Diabetes Mellitus.
• Patients requiring combination oral anti-diabetic therapy.
• Maintaining fasting and post-meal blood sugar levels.
• Supporting long-term glycemic control.

Product Features

Some of the key features of Vildagliptin and Metformin Sustained Release tablet that make it one of the best medicines are: 

• A combination of two clinically proven anti-diabetic medicines.
• Sustained Release (SR) formulation for extended action.
• Manufactured under WHO-GMP quality standards.
• High-quality formulation with consistent efficacy.
• Suitable for hospitals, clinics, and retail pharmacies.